CLSDF previously highlighted Source MDx, read the post (here)…there is nothing hotter than incorporating validated biomarkers under the umbrella of personalized medicine and that is what continues to transpire at the Source MDx Boulder headquarters. An impressive list of partners and clients of Source MDx include Abbott Labs (NYSE: ABT), Amgen (NASDAQ: AMGN), Celgene (NASDAQ: CELG), Eli Lilly (NYSE: LLY), and Pfizer (NYSE: PFE), to name a few. Now long time partner Pfizer has agreed to a new multi-year collaboration to incorporate the Source MDx platform into the Pfizer cancer and inflammation development programs. So that may be associated with one or more molecules in the Pfizer rheumatoid arthritis, transplantation rejection, osteoarthritis, breast, lung, pancreatic, and colorectal cancers, melanoma and thryroid neoplasm development work. I have not delved into the Q’s or K’s to unearth details, can anyone leave a comment about specifics on these programs at Pfizer?
Particulars on the deal are not plentiful but it appears to be a multi-year collaboration where validated candidate biomarkers will lead to joint commercial opportunities for potential companion diagnostics. So at some point in the future expect to hear about one or more predicative biomarkers in the clinic. Source MDx shall receive 1) an equity investment 2) a technology licensing fee and 3) R&D funding over the term of the agreement. Source MDx shall retain certain commercial rights to diagnostic biomarkers discovered through the agreement and, co-commercialization of any companion diagnostics that are developed as part of the collaboration is likely.
***Update*** Looks like GlobeImmune is in the lead to win CLSDF-Reader's Company of the Year award. Be sure to cast your vote at http://CLSDF.com. Voting ends 31 January!
If you enjoyed this post get free email updates (here).